This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MediciNova Appoints Geoffrey O'Brien As Vice President

SAN DIEGO, Oct. 16, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Geoffrey O'Brien, J.D./M.B.A. as Vice President.

"I am very pleased to announce Geoff's appointment and welcome him to the MediciNova executive management team," commented Yuichi Iwaki, M.D., Ph.D., MediciNova's President and Chief Executive Officer. "Geoff has added a tremendous amount of value to MediciNova and has made substantial contributions in a range of areas including business development, strategic planning, clinical development, legal matters, patents, finance and administration. In addition, Geoff has demonstrated strong leadership skills."

Mr. O'Brien has served as Senior Director, Business Development and Strategic Planning for MediciNova since 2012 and was Director, Business Development from 2009-2012. Prior to joining MediciNova, Mr. O'Brien was an equity research analyst covering pharmaceutical and biotechnology companies at UBS Securities, Nomura Securities, and Punk, Ziegel, and was a Vice President from 2004-2008. During his career as a senior equity research analyst on the sell side and buy side, he focused on clinical, scientific, financial, strategic and competitive analysis of development programs and marketed products. He used this analysis to predict the future prospects of both development-stage and established pharmaceutical and biotechnology companies. In addition, Mr. O'Brien executed acquisitions and equity offerings as a health care investment banker at Donaldson, Lufkin & Jenrette/Credit Suisse First Boston. Prior to graduate school, he worked on the successful development of a biotechnology product at The Liposome Company. Mr. O'Brien received a B.S. in chemistry, cum laude, from the University of Delaware and a J.D./M.B.A. from Vanderbilt University.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova's current strategy is to focus on its two prioritized product candidates, MN-166 (ibudilast) for neurological disorders, and MN-221 for the treatment of acute exacerbations of asthma. MN-166 is being developed in multiple indications, largely through investigator-sponsored trials and outside funding. MediciNova is engaged in strategic partnering and consortium funding discussions to support further development of both the MN-221 and MN-166 programs. For more information on MediciNova, Inc., please visit .
         Geoff O'Brien
         Vice President
         MediciNova, Inc.

MediciNova, Inc. Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,826.59 +14.40 0.08%
S&P 500 2,091.71 +2.57 0.12%
NASDAQ 5,122.3180 +19.51 0.38%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs